Organoidsciences Ltd. (KOSDAQ:476040)

Market Cap	199.34B
Revenue (ttm)	1.95B
Net Income (ttm)	-11.25B
Shares Out	6.55M
EPS (ttm)	-2,690.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,487
Average Volume	463,917
Open	30,050
Previous Close	29,850
Day's Range	29,700 - 30,800
52-Week Range	21,000 - 52,000
Beta	n/a
RSI	39.67
Earnings Date	n/a

About Accolade

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476040

Financial Performance

In 2024, Organoidsciences's revenue was 1.95 billion, an increase of 22.77% compared to the previous year's 1.59 billion. Losses were -11.25 billion, -70.93% less than in 2023.